[Effects of sodium ethamsylate on anticoagulant and anti-aggregation activity of vascular endothelium in hemorrhagic fever patients with renal syndrome].
OBJECTIVE
To elucidate effects of sodium ethamsylate (SE) on anticoagulant and antiaggregation activity of vascular endothelium in patients suffering from hemorrhagic fever with renal syndrome (HFRS).


METHODS
A trial of SE enrolled 70 HFRS patients (58 males, 12 females aged under 30 years) compatible by the disease severity. They were divided into two groups. 42 patients of the control group received standard therapy, 28 patients of the study group received adjuvant 12% solution of SE in daily dose 1500-2000 mg in the course of HFRS oliguria period. Hemostatic parameters were measured before and after the cuff test to investigate the condition of vascular wall with calculation of the athrombogenicity index (the ratio of the relevant indices before and after the cuff test). SE effects on vascular endothelium was assessed by a blind method.


RESULTS
In oliguria, both groups had baseline antiaggregation indices significantly higher than in the control. After the cuff test, control patients' indices tended to an increase while in the study group there was a marked decrease. The trend in anticoagulant activity of microvascular endothelium did not differ much with the groups. This picture persisted also in polyuria. In convalescence hemostasis was similar in both groups.


CONCLUSIONS
SE enhances antiaggregant activity of vascular endothelium in oliguria period of HFRS without affecting its anticoagulant properties. This is explained by a direct effect of SE on vascular endothelium.
I M
IM
Davidovich
B Z
BZ
Sirotin
T A
TA
Parshina
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D004979:Ethamsylate / Q000627:therapeutic use*; D005260:Female; D006480:Hemorrhagic Fever with Renal Syndrome / Q000097:blood* / Q000188:drug therapy; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
D006490:Hemostatics; D010975:Platelet Aggregation Inhibitors; D004979:Ethamsylate
Vliianie étamzilata natriia na antikoaguliatsionnuiu i antiagregatsionnuiu aktivnost' sosudistogo éndoteliia u bol'nykh gemorragicheskoĭ likhoradkoĭ s pochechnym sindromom.